Aroa Biosurgery Ltd (AU:ARX)
ASX:ARX
Want to see AU:ARX full AI Analyst Report?
ARX Stock Chart & Stats
AU$0.53
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.53
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.43 - AU$0.80
Previous CloseN/A
Volume195.72K
Average Volume (3M)302.12K
Market Cap
AU$214.46M
Enterprise ValueAU$204.53M
Total Cash (Recent Filing)AU$20.71M
Total Debt (Recent Filing)AU$6.14M
Price to Earnings (P/E)―
Beta0.49
Next Earnings
May 26, 2026EPS Estimate
<0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding345,902,650
10 Day Avg. Volume330,836
30 Day Avg. Volume302,123
Financial Highlights & Ratios
PEG Ratio0.65
Price to Book (P/B)1.73
Price to Sales (P/S)1.90
P/FCF Ratio-25.75
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$1.08Price Target Upside103.77% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)0.02
Revenue Forecast (FY)AU$117.28M
Bulls Say, Bears Say
Bulls Say
Revenue Growth MomentumAroa shows durable top-line expansion (≈16.9% revenue growth). Sustained revenue growth supports market penetration and recurring procedure-driven demand, underpinning longer-term scale benefits for commercial channels and product adoption across wound and soft-tissue markets.
Robust Balance Sheet And Low LeverageHigh equity ratio and favorable debt metrics provide financial flexibility to fund commercialization and R&D without heavy interest burdens. A conservative leverage profile reduces refinancing and solvency risk over the medium term.
Improving Margins And EBITDA TurnStrong gross margins and an EBITDA improvement to positive in 2025 indicate scalable unit economics and better cost absorption as sales grow. This supports sustainable operating leverage and improves the odds of durable profitability if trends continue.
Bears Say
Persistent Net Losses Reducing ROENegative net income has translated into negative ROE, signaling that current operations are not yet generating shareholder returns. Until net income turns sustainably positive, capital deployment and investor return prospects remain constrained.
Negative Free Cash FlowOngoing negative free cash flow means the business still relies on external funding or equity to finance growth and capex. This limits financial flexibility and increases sensitivity to funding conditions over the next several quarters.
Ongoing Profitability And EBIT Margin PressureDespite improving EBITDA, reported negative EBIT and net income indicate structural profit conversion issues. Continued pressure on operating margins could slow path to consistent net profitability and constrain reinvestment capacity.
Aroa Biosurgery Ltd News
ARX FAQ
What was Aroa Biosurgery Ltd’s price range in the past 12 months?
Aroa Biosurgery Ltd lowest share price was AU$0.43 and its highest was AU$0.80 in the past 12 months.
What is Aroa Biosurgery Ltd’s market cap?
Aroa Biosurgery Ltd’s market cap is AU$214.46M.
When is Aroa Biosurgery Ltd’s upcoming earnings report date?
Aroa Biosurgery Ltd’s upcoming earnings report date is May 26, 2026 which is in 7 days.
How were Aroa Biosurgery Ltd’s earnings last quarter?
Aroa Biosurgery Ltd released its earnings results on Nov 25, 2025. The company reported -AU$0.003 earnings per share for the quarter, missing the consensus estimate of AU$0.01 by -AU$0.013.
Is Aroa Biosurgery Ltd overvalued?
According to Wall Street analysts Aroa Biosurgery Ltd’s price is currently Undervalued.
Does Aroa Biosurgery Ltd pay dividends?
Aroa Biosurgery Ltd does not currently pay dividends.
What is Aroa Biosurgery Ltd’s EPS estimate?
Aroa Biosurgery Ltd’s EPS estimate is <0.01.
How many shares outstanding does Aroa Biosurgery Ltd have?
Aroa Biosurgery Ltd has 345,902,650 shares outstanding.
What happened to Aroa Biosurgery Ltd’s price movement after its last earnings report?
Aroa Biosurgery Ltd reported an EPS of -AU$0.003 in its last earnings report, missing expectations of AU$0.01. Following the earnings report the stock price went up 6.25%.
Which hedge fund is a major shareholder of Aroa Biosurgery Ltd?
Currently, no hedge funds are holding shares in AU:ARX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Aroa Biosurgery Ltd Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
AU$1.08 (103.77% Upside)
AU$1.08 (103.77% Upside)
Blogger Sentiment
Bullish
AU:ARX Sentiment 100%
Sector Average ―
Sector Average ―
Technicals
SMA
Positive
20 days / 200 days
Momentum
37.50%
12-Months-Change
Fundamentals
Return on Equity
-2.00%
Trailing 12-Months
Asset Growth
-1.71%
Trailing 12-Months
Company Description
Aroa Biosurgery Ltd
Aroa Biosurgery Limited, a regenerative medicine company, engages in the developing, manufacturing, and distributing medical devices for wound and tissue repair using extracellular matrix (ECM) technology in the United States and internationally. The company's products include Endoform Natural and Endoform Antimicrobia Restorative Bioscaffold for treating acute and chronic wounds; Myriad Matrix, an engineered ECM for soft tissue repair, reinforcement, and complex wounds; Myriad Morcells, a morcellized (powdered) format of Myriad Matrix for soft tissue repair and complex wounds; and Reinforced Bioscaffolds, a surgical product for use in ventral hernia repair and abdominal wall reconstruction. Aroa Biosurgery Limited was incorporated in 2007 and is headquartered in Auckland, New Zealand.
ARX Stock 12 Month Forecast
Average Price Target
AU$1.08
▲(103.77% Upside)
Technical Analysis
Polynovo
―
Cochlear
―
Cyclopharm Limited
―
EMvision Medical Devices Ltd.
―
4DMedical Ltd
―
Options Prices
Currently, No data available
---